{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CART19", "query": { "intervention": "CART19" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CART19&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T02:51:19.602Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02135406", "title": "CART-19 for Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "CART-19 T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2014-05", "completion_date": "2018-01-18", "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-09-03T02:51:19.602Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02135406" }, { "nct_id": "NCT01551043", "title": "Allo CART-19 Protocol", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphocytic Leukemia" ], "interventions": [ { "name": "CART-19", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2010-09", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2020-07-09", "last_synced_at": "2026-09-03T02:51:19.602Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01551043" }, { "nct_id": "NCT01626495", "title": "Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B Cell Leukemia", "B Cell Lymphoma" ], "interventions": [ { "name": "CART-19", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "24 Years", "sex": "ALL", "summary": "1 Year to 24 Years" }, "enrollment_count": 73, "start_date": "2011-08-17", "completion_date": "2019-07-11", "has_results": true, "last_update_posted_date": "2020-03-23", "last_synced_at": "2026-09-03T02:51:19.602Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01626495" }, { "nct_id": "NCT02935543", "title": "CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Acute Lymphoblastic" ], "interventions": [ { "name": "CART 19", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2016-10", "completion_date": "2018-12-12", "has_results": true, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-09-03T02:51:19.602Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02935543" }, { "nct_id": "NCT06839976", "title": "CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "SLE", "Systemic Lupus Erythematosus (SLE)", "CAR T Cell", "CART19", "Cell Therapy", "Lupus", "Lupus Nephritis (LN)" ], "interventions": [ { "name": "CART19", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "12 Years to 29 Years" }, "enrollment_count": 24, "start_date": "2025-05-06", "completion_date": "2030-02-28", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-03T02:51:19.602Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06839976" }, { "nct_id": "NCT02529813", "title": "CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Biphenotypic Leukemia", "Acute Lymphoblastic Leukemia", "Blasts 5 Percent or More of Bone Marrow Nucleated Cells", "CD19 Positive", "Minimal Residual Disease", "Non-Hodgkin Lymphoma", "Small Lymphocytic Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage IV Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Tisagenlecleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "80 Years", "sex": "ALL", "summary": "1 Year to 80 Years" }, "enrollment_count": 26, "start_date": "2015-12-16", "completion_date": "2021-11-08", "has_results": false, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-09-03T02:51:19.602Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02529813" }, { "nct_id": "NCT02476734", "title": "FDG-PET/CT Imaging as Early Predictor of DP", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "There is no intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2014-08", "completion_date": "2018-08", "has_results": false, "last_update_posted_date": "2023-07-11", "last_synced_at": "2026-09-03T02:51:19.602Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02476734" }, { "nct_id": "NCT02624258", "title": "Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "CD19 RNA redirected autologous T-cells (RNA CART19 cells)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "18 Years to 24 Years" }, "enrollment_count": 2, "start_date": "2015-11", "completion_date": "2019-12-06", "has_results": false, "last_update_posted_date": "2020-05-21", "last_synced_at": "2026-09-03T02:51:19.602Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02624258" }, { "nct_id": "NCT02374333", "title": "Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphocytic Leukemia", "Diffuse Large Cell Lymphoma" ], "interventions": [ { "name": "huCART19", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "24 Years", "sex": "ALL", "summary": "1 Year to 24 Years" }, "enrollment_count": 81, "start_date": "2014-03-25", "completion_date": "2021-09-02", "has_results": false, "last_update_posted_date": "2021-09-23", "last_synced_at": "2026-09-03T02:51:19.602Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02374333" }, { "nct_id": "NCT02030847", "title": "Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options" ], "interventions": [ { "name": "CART-19", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2014-02-27", "completion_date": "2018-04-26", "has_results": true, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-09-03T02:51:19.602Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02030847" } ] }